Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary endpoint and the only time stamp out of 10 in which the candidate was ...
Unity Biotechnology and Mammoth Biosciences are both turning toward cost-saving measures, prompting layoffs at both companies. Unity’s restructuring comes along with 36-week results from its phase 2b ...
It really happened. Donald Trump won convincingly, just as I predicted. So I don’t need to publish a retraction or correction today like we are due from so many liberals for their substitution of ...
Shares of Unity Biotechnology Inc. (NASDAQ:UBX) sank 28.8% to close at $1.30 March 24 as a top-line readout of its phase IIb Aspire study testing UBX-1325 head-to-head against aflibercept in diabetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results